title: Effect of a new bombesin receptor antagonist, (E)-alkene bombesin isostere, on amylase release from rat pancreatic acini.
abstract: The short-chain pseudopeptide, [D-Phe6, Leu13 psi (CH2NH)Leu14]bombesin(6-14) (RDI), is reported to be a potent antagonist of bombesin, and development of this type of compound has greatly contributed to the investigation of biological actions of bombesin and its related peptides. We recently synthesized (E)-alkene bombesin isostere by replacing the peptide bond with an (E)-double bond: [D-Phe6, Leu13 psi [(E)CH = CH]Leu14] bombesin(6-14) (EABI). The present study examined the effect of EABI on amylase release from rat pancreatic acini. EABI showed no agonistic activity at concentrations up to 1 microM, and RBI showed slight agonistic activity at concentrations > 10 nM. EABI caused a dose-dependent inhibition of amylase release stimulated by 0.1 nM bombesin, with an IC50 of 6.7 +/- 1.7 nM, and induced almost-complete inhibition at 0.3 microM. RDI caused a dose-dependent inhibition of amylase release, with an IC50 of 68.7 +/- 16 nM. EABI caused a parallel and rightward shift of the entire dose-response curve of bombesin-stimulated amylase release, and the degree of the shift was dependent on the concentrations of EABI. EABI (100 nM) and RDI (100 nM) inhibited amylase releases stimulated by gastrin-releasing peptide (1 nM) and neuromedin-C (1 nM). In contrast, amylase release stimulated by cholecystokinin octapeptide (0.1 nM), carbachol (10 microM), vasoactive intestinal peptide (1 nM), and gastrin-17 (10 nM) was not inhibited by EABI and RDI. The results indicate that EABI is a potent and specific bombesin receptor antagonist.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: First Department of Surgery, Kyoto University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Wada
authors.forename: R
authors.initials: R
authors.lastname: Doi
authors.forename: R
authors.initials: R
authors.lastname: Hosotani
authors.forename: S
authors.initials: S
authors.lastname: Higashide
authors.forename: T
authors.initials: T
authors.lastname: Ibuka
authors.forename: H
authors.initials: H
authors.lastname: Habashita
authors.forename: K
authors.initials: K
authors.lastname: Nakai
authors.forename: N
authors.initials: N
authors.lastname: Fujii
authors.forename: M
authors.initials: M
authors.lastname: Imamura
mesh_terms: D000595:Amino Acid Sequence; D000681:Amylases / Q000378:metabolism*; D000818:Animals; D001839:Bombesin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D008969:Molecular Sequence Data; D010179:Pancreas / Q000187:drug effects* / Q000201:enzymology* / Q000378:metabolism; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018004:Receptors, Bombesin / Q000037:antagonists & inhibitors*
chemical_list: D010446:Peptide Fragments; D018004:Receptors, Bombesin; C091873:bombesin (6-14), Phe(6)-Leu(13)-psi(CH2NH)-Leu(14)-; C094749:bombesin (6-14)-NH2, Phe(6)-Gln(7)-psi(CHCH)Leu(14)-; D000681:Amylases; D001839:Bombesin